MogrifyAE will transform the lives of patients with degenerative diseases through a novel class of in vivo reprogramming therapies.
Mogrify has raised $10.0M in total funding. The most recent round was Series A. The last funding was announced in October 2023.
Mogrify's investors include Ahren Innovation Capital, Parkwalk Advisors, 24 Haymarket, Astellas Venture Management, Aerion Partners.
Mogrify is headquartered in Cambridge, United Kingdom.
MogrifyAE will transform the lives of patients with degenerative diseases through a novel class of in vivo reprogramming therapies.
Mogrify is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Mogrify — Funding & Investors." VCBacked, October 2, 2023, https://www.vcbacked.co/company/mogrify. Accessed July 21, 2026.
VCBacked. (2023). Mogrify — Funding & Investors. Retrieved July 21, 2026, from https://www.vcbacked.co/company/mogrify
{{cite web |title=Mogrify — Funding & Investors |url=https://www.vcbacked.co/company/mogrify |website=VCBacked |access-date=July 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated